Clinical Trial Goal
To find out:
- The highest dose of SENTI-202 that's safe to give
- If SENTI-202 is safe and works well to treat CD33+, FLT3+, IDH1+ and/or IDH2+ AML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 to 74 years of age
- Have AML or MDS that has relapsed or is refractory
- Have one of the following mutations:
- CD33
- FLT3
- IDH1
- IDH2
- Have not had an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Have not had CAR T cell or NK cell therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
SENTI-202 is made from natural killer cells (a kind of immune cell). The NK cells are grown in a lab (expanded) to create SENTI-202. Doctors think the SENTI-202 will attack and kill cancer cells.
Before the NK-cell infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:
Before the NK-cell infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:
- Cytarabine – Given as intravenous (IV) infusions
- Fludarabine – Given as IV infusions
Then, the NK cells are given to you through an IV infusion. The dose of cells you’ll get depends on when you start the trial and how safe it has been.
The clinical trial doctors will watch you closely. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved SENTI-202.
Contacts
Amy Alford, MA, 650-239-2030, clinicaltrials@sentibio.com
Rochelle Emery, MD, 650-239-2030, clinicaltrials@sentibio.com
Locations
Sponsors
lead: Senti Biosciences
